Diaceutics (DXRX) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Nov 2022 07:00 AM
RNS
Sub-optimal testing impacts on cancer patients
31 Oct 2022 02:20 PM
RNS
PDMR Shareholding/Share Incentive Plan
05 Oct 2022 05:03 PM
RNS
PDMR Shareholding/Share Incentive Plan
05 Oct 2022 07:00 AM
RNS
Purchase of Shares and PDMR Shareholding
27 Sep 2022 07:00 AM
RNS
Half-year Report
12 Sep 2022 12:38 PM
RNS
PDMR Shareholding/Share Incentive Plan
08 Sep 2022 07:00 AM
RNS
Notice of Results and Presentations
08 Aug 2022 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
26 Jul 2022 07:00 AM
RNS
Trading Update and Notice of Results
22 Jul 2022 05:45 PM
RNS
PDMR Shareholding/Share Incentive Plan
13 Jun 2022 07:00 AM
RNS
Multi-year contract with top five global pharma
07 Jun 2022 07:00 AM
RNS
New AI and ML Capabilities Enhance DXRX Platform
31 May 2022 12:12 PM
RNS
PDMR Shareholding/Share Incentive Plan
27 May 2022 04:31 PM
RNS
Share Options and PDMR Shareholdings
26 May 2022 03:00 PM
RNS
Result of AGM
11 May 2022 02:34 PM
RNS
PDMR Shareholding/Share Incentive Plan
09 May 2022 04:37 PM
RNS
Exercise of Warrant & Total Voting Rights
05 May 2022 07:00 AM
RNS
Contract Win
29 Apr 2022 05:22 PM
RNS
PDMR Shareholding/Share Incentive Plan
28 Apr 2022 02:09 PM
RNS
Notice of AGM and Posting of Annual Report
07 Apr 2022 07:00 AM
RNS
Purchase and Sale of Shares and PDMR Shareholdings
06 Apr 2022 01:13 PM
RNS
PDMR Shareholding/Share Incentive Plan
05 Apr 2022 03:49 PM
RNS
Conversion of Convertible Loan Notes & TVR
01 Apr 2022 07:00 AM
RNS
Issue of Share Options / PDMR Shareholdings
31 Mar 2022 05:38 PM
RNS
PDMR Shareholding/Share Incentive Plan
22 Mar 2022 02:43 PM
RNS
Final Results
22 Mar 2022 07:00 AM
RNS
Notice of 2021 Full Year Results
18 Mar 2022 02:09 PM
RNS
Confirmation of Directorate Change
16 Mar 2022 05:49 PM
RNS
Holding(s) in Company
16 Mar 2022 07:00 AM
RNS
Approval by CMS for enhanced data access
02 Mar 2022 05:37 PM
RNS
PDMR Shareholding/Share Incentive Plan
21 Feb 2022 07:00 AM
RNS
Investor Presentation
14 Feb 2022 06:26 PM
RNS
PDMR Shareholding/Share Incentive Plan
14 Feb 2022 07:00 AM
RNS
Contract with leading life sciences company
04 Feb 2022 11:26 AM
RNS
Director/PDMR Shareholding
11 Jan 2022 07:01 AM
RNS
Directorate Change
11 Jan 2022 07:00 AM
RNS
Trading Update and Notice of Results
04 Jan 2022 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
14 Dec 2021 07:00 AM
RNS
Contract Win
09 Dec 2021 07:00 AM
RNS
Test Signal Launch and Contract Wins
01 Dec 2021 05:22 PM
RNS
PDMR Shareholding/Share Incentive Plan
09 Nov 2021 04:57 PM
RNS
PDMR Shareholding/Share Incentive Plan
01 Oct 2021 01:19 PM
RNS
PDMR Shareholding/Share Incentive Plan
01 Oct 2021 12:32 PM
RNS
Holding(s) in Company
28 Sep 2021 07:00 AM
RNS
Purchase/Transfer of Shares and PDMR Shareholdings
21 Sep 2021 07:00 AM
RNS
Nominated as finalists for Health Tech Awards 2021
14 Sep 2021 07:00 AM
RNS
Half-year Report
13 Sep 2021 07:00 AM
RNS
DXRX Platform Contract Win
08 Sep 2021 07:00 AM
RNS
Two new experts join the Diaceutics Advisory Panel
01 Sep 2021 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan

Diaceutics PLC, a global leader in the field of precision medicine, holds a significant position on the London Stock Exchange (LSE). As part of the dynamic financial ecosystem facilitated by the London Stock Exchange Group (LSEG), Diaceutics PLC contributes to the global financial landscape.

The Diaceutics share price and DXRX share price are key indicators of the company's market performance. These metrics are closely monitored by investors to assess the company's financial health and make informed investment decisions.

Founded in 2005, Diaceutics PLC is headquartered in Belfast, United Kingdom. The company has been a pioneer in the field of diagnostic testing, collating large amounts of laboratory, patient, claims, and payor data which it uses to deliver diagnostic testing strategies to its clients. Over the years, Diaceutics PLC has amassed a set of data from over 52,515 laboratories, showing disease volumes and 481 million de-identified patient records globally in 53 countries. This data collection has allowed the company to accumulate a proprietary database of laboratory capabilities across the industry.

Diaceutics PLC provides services to 39 global pharmaceutical companies and is focused on optimising its clients’ strategies for the development and launch of precision medicines. Precision medicines are a class of drug tailored to individual patient groups dependent on molecular or genetic factors of the individual. Today, they are used for treatment in oncology as well as other disease areas such as multiple sclerosis and rheumatoid arthritis.

Being listed on the LSE, Diaceutics PLC is part of the vibrant financial ecosystem facilitated by the London Stock Exchange Group (LSEG). LSEG, a leading global financial markets infrastructure and data provider, plays a crucial role in supporting the financial stability and growth of communities and economies globally.

In conclusion, Diaceutics PLC, with its strategic focus on precision medicine and its status as a company listed on the LSE, represents a noteworthy entity in the financial markets landscape facilitated by LSEG. Its share price, referred to as both Diaceutics share price and DXRX share price, are key considerations for investors, reflecting the company's market performance. As part of the vibrant LSEG ecosystem, Diaceutics PLC contributes to the broader financial markets infrastructure, underscoring its significance in the global financial community.

UK 100